Based on the inhibitory mechanism towards JAK1/2, the Food and Drug Administration (FDA), in 2019, extended approval of the use of ruxolitinib for the treatment of GVHD in acute, steroid-resistant cases in adults and children aged 12 and over. The gene discussed is JAK1; the disease is graft versus host disease.